Dr. Ryan Moy
Claim this profileNYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
Studies Colorectal Cancer
Studies Cystic Tumor
6 reported clinical trials
14 drugs studied
Area of expertise
1Colorectal Cancer
Stage IV
Mismatch Repair Deficiency positive
Stage III
2Cystic Tumor
Stage IV
Affiliated Hospitals
Clinical Trials Ryan Moy is currently running
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
BMS-986340 + Nivolumab/Docetaxel
for Cancer
This trial tests a new drug, BMS-986340, alone and with other cancer treatments (nivolumab and docetaxel) in patients with advanced solid tumors. The goal is to find out if it is safe and effective in treating these cancers.
Recruiting1 award Phase 1 & 26 criteria
More about Ryan Moy
Clinical Trial Related2 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Ryan Moy has experience with
- 9-ING-41
- BMS-936558-01
- BMS-986340
- Docetaxel
- BAY 1895344
- Fluorouracil
Breakdown of trials Ryan Moy has run
Colorectal Cancer
Cystic Tumor
Cancer
Parotid Gland Cancer
Cervical Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Ryan Moy specialize in?
Is Ryan Moy currently recruiting for clinical trials?
Are there any treatments that Ryan Moy has studied deeply?
What is the best way to schedule an appointment with Ryan Moy?
What is the office address of Ryan Moy?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.